论文部分内容阅读
特发性肺纤维化(IPF)是一种严重的炎症性疾病,预后差,中位生存期4～6年。病情进展速度不一,治疗效果常难以预测。而治疗效果是决定预后的重要因素。 作者对25例特发性肺纤维化患者进行了回顾性研究,目的在于明确在治疗前与疗效有关的因素;评估环磷酰胺(CTX)对疾病进展的影响。25例连续观察的IPF患者,女性8例,男性17例,平均年龄48±15岁,其中吸烟者10例。IPF诊断依据是:进行性气短、双肺爆裂音、杵状指、胸片两肺弥散阴影,肺功能试验显示
Idiopathic pulmonary fibrosis (IPF) is a serious inflammatory disease with a poor prognosis, with a median survival of 4 to 6 years. The progress of the disease varies, the treatment effect is often difficult to predict. The treatment effect is an important factor in determining the prognosis. The authors conducted a retrospective study of 25 patients with idiopathic pulmonary fibrosis with the aim of identifying factors that were related to efficacy prior to treatment and assessing the impact of cyclophosphamide (CTX) on the progression of the disease. Twenty-five consecutive IPF patients were observed, including 8 females and 17 males, with an average age of 48 ± 15 years, of whom 10 were smokers. IPF diagnosis is based on: shortness of breath, lungs crackle, clubbing, chest radiographs of the two lungs, lung function test showed